Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Children's Oncology Group
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01353300
First received: May 12, 2011
Last updated: May 26, 2011
Last verified: May 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: The identification of gene mutations in young patients with pleuropulmonary blastoma syndrome may allow doctors to better understand the genetic processes involved in the development of some types of cancer, and may also help doctors identify patients who are at risk for cancer.
PURPOSE: This research study studies gene mutations in samples from young patients with pleuropulmonary blastoma syndrome at risk for developing cancer.
| Condition | Intervention |
|---|---|
|
Brain and Central Nervous System Tumors Hereditary Wilms Tumor Kidney Cancer Liver Cancer Neuroblastoma Pleuropulmonary Blastoma Sarcoma |
Genetic: DNA analysis Genetic: cytogenetic analysis Genetic: gene expression analysis Genetic: gene rearrangement analysis Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: polymorphism analysis Other: laboratory biomarker analysis Other: medical chart review |
| Study Type: | Observational |
| Official Title: | Investigation of DICER1 in Cystic Nephroma and Cystic Partially Differentiated Nephroblastoma |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Blastoma
Hepatoblastoma
Kidney Cancer
Liver Cancer
Malignant Mesenchymal Tumor
Medulloblastoma
Medulloblastoma, Childhood
Neural Crest Tumor
Neuroblastoma
Pleuropulmonary Blastoma
Renal Cancer
Soft Tissue Sarcoma
Wilms' Tumor
U.S. FDA Resources
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Relationship between DICER1 mutations and tumor pathogenesis in cystic nephromas and cystic partially differentiated nephroblastomas outside of families with PPB nephroblastomas [ Designated as safety issue: No ]
| Estimated Enrollment: | 31 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To determine if DICER1 mutations contribute to tumor pathogenesis in cystic nephromas and cystic partially differentiated nephroblastomas outside of families with pleuropulmonary blastoma (PPB) syndrome.
OUTLINE: Archived DNA samples are analyzed for DICER1 mutation by qPCR and directly sequenced using BigDye Terminator chemistry. Results are then compared against the single nucleotide polymorphism (SNP) database.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of pleuropulmonary blastoma syndrome
- Normal tissue samples, if available
- Parental and sibling DNA samples, if available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353300
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353300
Sponsors and Collaborators
Children's Oncology Group
Investigators
| Principal Investigator: | Dana A. Hill, MD | Children's Research Institute |
More Information
Additional Information:
No publications provided
| Responsible Party: | Gregory H. Reaman, Children's Oncology Group - Group Chair Office |
| ClinicalTrials.gov Identifier: | NCT01353300 History of Changes |
| Other Study ID Numbers: | CDR0000700282, COG-AREN11B2 |
| Study First Received: | May 12, 2011 |
| Last Updated: | May 26, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
embryonal childhood rhabdomyosarcoma cystic nephroma neuroblastoma childhood medulloblastoma |
childhood hepatoblastoma stromal predominant Wilms tumor hereditary Wilms tumor pleuropulmonary blastoma |
Additional relevant MeSH terms:
|
Central Nervous System Neoplasms Pulmonary Blastoma Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site |
Neoplasms, Complex and Mixed Nervous System Diseases Nervous System Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
ClinicalTrials.gov processed this record on March 03, 2015